NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK

Introduction Population aging is a major global challenge with estimated 1.6 billion people will be over 65 by 2050. Aging is the main risk factor for many chronic diseases, including Alzheimer's disease (AD). Hong Kong features one of the world's largest proportions of older adults and highest life expectancy and therefore, Hong Kong will face a particular heavy burden on caring of elderly citizens with dementia. Hence, to better planning for caring the aging population within the community, there is a need for robust, community-based data integrating clinical, cognitive, biomarker, and neuroimaging metrics in ethnic Chinese populations. Research Objectives

• Compare validity of clinical assessments, clinical diagnoses, and blood biomarker panels for identifying clinically normal, MCI, and AD using MRI scan and PET imaging as gold standard in a community-based setting.
• Validate blood biomarker panels for predicting conversion from clinically normal to MCI-AD, AD, non-AD MCI/dementia, and MCI to AD/non-AD dementia.
• Explore novel blood and imaging biomarkers for AD diagnosis and progression. Study Design Prospective, community-based cohort study lasting for 5-year duration and expected average 2-3 years longitudinal follow-up for participants.
• Pre-screening of 6,000 community-dwelling elderly at community centers (5-min MoCA, no consent required).
• Enrollment of ~2,500 participants for cross-sectional cohort with informed consent.
• Participants selection and down select as detailed in next section. Participants will undergo clinical, cognitive, and functional assessments; demographic and clinical data collected at local centers.
• Blood sampling by research personnel (HKUST, HKCeND, TWC) with fasting blood processed, analyzed, and stored at HKUST/HKCeND.
• Proteomic results used to stratify participants into low, intermediate, or high risk; imaging follow-up based on stratification. Setting
• Recruitment at district-level community centers for elderly across Hong Kong.
• Centers act as support hubs for healthy aging and provide access to a representative sample.
• Collaboration with Tung Wah College and Tung Wah Group of Hospitals' network. Participant Selection and Down-Selection via Multi-Stage Protocol
• Target: Community-dwelling older adults (Han Chinese, age 60-75) identified through community centers.
• Stage 1 - Brief cognitive screening: 6,000 screened via MoCA-5min; subgroup assignment by percentile (dementia: <2%, mild cognitive impairment (MCI): 2-16%, cognitively normal (CN): >16%).
• Stage 2 - Cross-sectional cohort: 2,500 enrolled, informed consent, clinical and physical assessments, blood tests, clinical diagnosis (DSM-IV). Distribution of subgroups selected: dementia 14%, MCI 43%, and CN 43%.
• Stage 3 - Proteomic sub-cohort: 750 selected for plasma proteomics (21- protein panel + pTau217) and stratified by proteomic score (negative < 21, intermediate 21-52, positive > 52).
• Stage 4 - Imaging sub-cohort: 350 selected for advanced imaging (MRI, amyloid PET) based on clinical diagnosis and proteomic result. All assessments repeated at follow-up for longitudinal monitoring. Variables and Measurement
• Brief Cognitive Function: MoCA-5min: Memory, attention, language, abstraction, orientation.
• Demographics: Age, sex, ethnicity, marital status, family history, education, socio-economic status, occupation.
• Anthropometrics: Height (stadiometer), weight (calibrated scale), BMI calculation.
• Cardiovascular Health: BP, pulse (automated monitor).
• Clinical Assessment Battery: MoCA (full), ADL, iADL, FRAIL, PHQ-9, MBIS.
• Clinical Diagnosis: NIA-AA criteria, applied by registered physicians.
• Blood Tests: 1) Chemistry: Liver, kidney, bone/muscle enzymes, lipids, glucose; 2) Haematology: CBC; 3) Proteomics: Olink, Simoa, Fujirebio, Alamar Biosciences platforms for plasma protein profiling; 4) Genomics (optional): Whole-genome sequencing, methylation arrays, RNA-seq for AD risk loci and gene expression.
• Amyloid/Tau PET and MRI Brain Imaging: PET: Gold standard for amyloid/ tau detection; MRI for structural changes and regional volumetrics.
• Imaging repeated at 2-3 years follow-up for longitudinal assessment.

Inclusion criteria

• Mentally capable of providing informed consent, with or without an informant present
• Willing and able to undergo blood draw and complete study related assessments; willing to be contacted for follow-up

Exclusion criteria

• Lacks capacity to consent even with an informant present
• Refuses or is unable to provide blood samples or complete essential assessments
• Currently enrolled in another clinical trial that could interfere with this study
• Known illness that prevents longitudinal follow up or uncontrolled medical illness such as neurodevelopmental disorder, neurodegenerative disease, epilepsy, central nervous system infection, neuroinflammatory diseases, brain tumor, cerebrovascular diseases, history of major psychiatric illness, history of major head injury with altered consciousness, sexually transmitted disease including HIV and syphilis, visual and auditory disability, history of alcohol dependence, substance use disorder, systemic autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, or malignancy.
• Active delirium or evidence of reversible/secondary causes of cognitive impairment (e.g., vitamin B12 deficiency, hypothyroidism) until treated/ stabilized